Abstract: A serotype 2 Marek's disease vaccine comprising a cloned strain designated as 301B/1 has been derived from a field isolate. This strain is characterized by superior levels of replicative ability and protectivity in chickens as compared to existing commercial serotype 2 strains, and it is virtually nonpathogenic. 301B/1 is particularly useful in the formulation of highly efficacious bivalent and polyvalent vaccines.
Type:
Grant
Filed:
July 10, 1987
Date of Patent:
January 23, 1990
Assignee:
The United States of America, as represented by the Secretary of Agriculture
Abstract: The full length DNA sequence encoding the mature cellobiohydrolase II(CHBII), as well as the DNA sequence encoding the CBHII signal sequence, have been isolated and cloned from the fungus Trichoderma reesei. Recombinant vectors comprising these sequences, and yeast hosts transformed with such vectors are disclosed. Also disclosed are methods for constructing the vectors and hosts according to the invention, as well as methods for expressing the disclosed sequences. CBHII is involved in hydrolysis of cellulose.
Type:
Grant
Filed:
January 30, 1986
Date of Patent:
January 16, 1990
Assignee:
Oy Alko AB
Inventors:
Jonathan Knowles, Merja Penttila, Tuula Teeri, Helena Nevalainen, Irma Salovuori, Paivi Lehtovaara-Helenius
Abstract: A method for increasing the rate of chemical reactions involving the conversion of at least one reactant to at least one product involves contacting the reactant with an appropriate monoclonal antibody under conditions permitting the formation of a complex between the antibody and the reactant. The complexed reactant is converted to the product which is then released from the complex. The monoclonal antibody may employ a cofactor and may be directed to a known substrate of an enzyme. Methods for preparing such monoclonal antibodies are also disclosed.
Abstract: A genetically stable nontoxinogenic form of the Ogawa 395 strain of Vibrio cholerae which has a deletion mutation in both copies of the A.sub.1 -peptide-encoding gene, resulting in the loss of a gene sequence required for expression of a toxic A.sub.1 peptide is disclosed, as well as plasmids and methods for making the strain. The strain is useful as a live or dead oral vaccine.
Type:
Grant
Filed:
April 29, 1983
Date of Patent:
November 21, 1989
Assignee:
President and Fellows of Harvard College
Abstract: Process for transformation of Yarrowia lipolytica, vectors useful therefor comprising DNA of a microbial vector and chromosomal DNA of Y. lipolytica and transformants comprising said vectors in E. coli and Y. lipolytica, and integrative shuttle vectors for Escherichia-Yarrowia transgeneric cloning. Said vectors or subclones thereof enable creation of Y. lipolytica cloning vectors into which specific or random segments of DNA can be inserted and the resulting vectors used to transform a suitable host microbe, especially Y. lipolytica, to improve the fermentation characteristics thereof and hence their industrial utilization.The methodology described permits the cloning of genes from a gene library of Y. lipolytica by complementation with an integrating vector.
Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human phospholipase inhibitor polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human phospholipase inhibitor polypeptide. In appropiate hosts these DNA sequences permit the production of human phospholipase inhibitor polypeptides.
Type:
Grant
Filed:
January 10, 1985
Date of Patent:
November 7, 1989
Assignee:
Biogen, Inc.
Inventors:
Barbara P. Wallner, R. Blake Pepinsky, Jeffrey L. Garwin
Abstract: Disclosed is a process for producing tryptophan by transforming a host microorganism belonging to the genus Corynebacterium or Brevibacterium with a recombinant DNA of a DNA fragment containing a gene involved in the biosynthesis of tryptophan and a vector DNA, culturing the transformant in a nutrient medium, accumulating tryptophan in the culture medium and recovering tryptophan therefrom.
Type:
Grant
Filed:
July 16, 1987
Date of Patent:
October 17, 1989
Assignee:
Kyowa Hakko Kogyo Co., Ltd.
Inventors:
Akio Ozaki, Ryoichi Katsumata, Tetsuo Oka
Abstract: Human tissue plasminogen activator (t-PA) is produced in useful quantities using recombinant DNA techniques. The invention disclosed thus enables the production of t-PA free of contaminants with which it is ordinarily associated in its native cellular environment. Methods, expression vehicles and various host cells useful in its production are also disclosed.
Type:
Grant
Filed:
April 21, 1988
Date of Patent:
August 1, 1989
Assignee:
Genentech, Inc.
Inventors:
David V. Goeddel, William J. Kohr, Diane Pennica, Gordon A. Vehar
Abstract: The subject invention concerns a process for stabilizing foreign proteins within the cell of E. coli microbes infected with genetic elements encoding said protein production.
Type:
Grant
Filed:
August 23, 1985
Date of Patent:
July 4, 1989
Assignee:
The Research Foundation of State University of New York
Abstract: Biologically active heteropolymeric protein composed of a plurality of subunits, each subunit being synthesized by a cell having an expression vector heterologous DNA encoding the subunit.
Type:
Grant
Filed:
November 2, 1983
Date of Patent:
June 20, 1989
Assignee:
Integrated Genetics, Inc.
Inventors:
Vermuri B. Reddy, Nancy Hsiung, Anton K. Beck, Edward G. Bernstine
Abstract: A novel modified human insulin of the general formula: ##STR1## wherein R is a hydrophobic or charged amino acid or a di- or tripeptide group, comprising a hydrophobic or charged amino acid or an amide or ester of said amino acid or peptide and its use as starting material for the preparation of human insulin.
Type:
Grant
Filed:
August 20, 1985
Date of Patent:
June 20, 1989
Assignee:
Akzo N.V.
Inventors:
Gijsbert W. K. Van Dedem, Francois E. A. Van Houdenhoven
Abstract: An expression vector having two structural genes that form a synthetic operon expressed under the control of a single regulatory sequence. The operon genes correspond to the structural component of naturally occurring genes whose expression is controlled by distinct separate regulatory sequences. The operon genes code for enzymes in a biosynthetic pathway for producing a desired compound, and at least one of those operon genes is feedback derepressed. The vector is used to transform host cells that are cultured to produce the desired product.
Type:
Grant
Filed:
September 24, 1984
Date of Patent:
June 13, 1989
Assignees:
Biotechnica International, Inc., H. J. Heinz Company
Abstract: A symbiosis plasmid from a fast-growing Rhizobium japonicum donor strain can be transferred to Rhizobium recipient strains, the recipient strains being previously incapable of forming an effective symbiotic relationship with plants of certain Glycine (e.g. soybean) varieties. The recipient strains harboring the symbiosis plasmid will form effective symbioses with soybean plants of said certain varieties, the transferred symbiosis plasmid conferring the host range or specificity of the donor strain on the recipient strains. Methods, strains, and plasmids useful for practice of this invention are also provided.
Type:
Grant
Filed:
June 1, 1984
Date of Patent:
April 4, 1989
Assignee:
Lubrizol Genetics, Inc.
Inventors:
Edward R. Appelbaum, Thomas J. McLoughlin, Michael P. O'Connell
Abstract: Altered and native immunoglobulins, including constant-variable region chimeras, are prepared in recombinant cell culture. The immunoglobulins contain variable regions which are immunologically capable of binding predetermined antigens. Methods are provided for refolding directly expressed immunoglobulins into immunologically active form.
Type:
Grant
Filed:
April 8, 1983
Date of Patent:
March 28, 1989
Assignee:
Genentech, Inc.
Inventors:
Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
Abstract: Recombinant DNA expression vectors for use in Bacillus and other host cells are disclosed. The vectors comprise the veg promoter sequence of Bacillus subtilis, a novel ribosome binding site-containing sequence and a sequence that codes for a functional polypeptide. The ribosome binding site-containing sequence is synthesized in accordance with conventional procedures while the veg promoter sequence can be obtained from E. coli K12 JA221/pMS480 (NRRL B-15258). Various sequences that codes for functional polypeptides and method for their expression in Bacillus are also disclosed.
Type:
Grant
Filed:
September 26, 1984
Date of Patent:
November 8, 1988
Assignee:
Eli Lilly and Company
Inventors:
Steven Kovacevic, James R. Miller, Hansen M. Hsiung
Abstract: The actinomycete "Actinomadura sp." designated in our culture collection as Strain No. G455-101 has been deposited with the American Type Culture Collection under the Accession Number ATCC No. 31491. The taxonomic description of this microorganism is presented in detail in the specification as are instructions for fermenting aqueous nutrient media with it to produce the BBM 928 antibiotic complex. The BBM 928 complex has utility as an antibacterial agent against gram-positive and acid fast bacteria and exhibits antitumor activity against experimental animal tumors.
Abstract: The bacterium producing thermostable .alpha.-amylases of this invention is an anaerobic bacterium belonging to Clostridium. The thermostable .alpha.-amylases of this invention is novel .alpha.-amylases which are excellent in thermostability and acid resistance and have a slight calcium requirement. Said .alpha.-amylases are obtained by culturing the aforesaid bacteria and collecting the .alpha.-amylases from the culture. When the aforesaid .alpha.-amylase is used, sugar production process can be greatly rationalized.
Type:
Grant
Filed:
November 7, 1985
Date of Patent:
October 18, 1988
Assignees:
Hitachi, Ltd., Hitachi Plant Engineering & Construction Co. Ltd.
Abstract: Cloning and expression vectors for hepatitis B HBxAg, cell cultures containing those vectors, and diagnostic systems and methods for assaying for the presence of HBxAg and anti-HBxAg in a body sample are disclosed.
Type:
Grant
Filed:
September 7, 1984
Date of Patent:
October 11, 1988
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Ann M. Moriarty, Hannah Alexander, Richard A. Lerner
Abstract: Disclosed is a process for producing L-arginine by transforming a host microorganism belonging to the genus Corynebacterium or Brevibacterium with a recombinant DNA of a DNA fragment containing a gene involved in the biosynthesis of L-arginine and a vector DNA, culturing the transformant in a nutrient medium, accumulating L-arginine in the culture medium and recovering L-arginine therefrom.
Type:
Grant
Filed:
August 31, 1984
Date of Patent:
October 4, 1988
Assignee:
Kyowa Khkko Kogyo Co., Ltd.
Inventors:
Ryoichi Katsumata, Haruhiko Yokoi, Tetsuo Oka
Abstract: A cDNA having a base sequence for human skin fibroblast collagenase has been cloned and characterized and the amino acid sequence of the human skin fibroblast protein has been determined.
Type:
Grant
Filed:
November 12, 1985
Date of Patent:
September 20, 1988
Assignee:
Washington University
Inventors:
Arthur Z. Eisen, Gregory I. Goldberg, Eugene A. Bauer